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Ken-ichi Yoshino1, Ushio Kikkawa1* and Kazuyoshi Yonezawa1ˆAbstract
Background: mTOR is a genetically conserved serine/threonine protein kinase, which controls cell growth,
proliferation, and survival. A multifunctional protein CAD, catalyzing the initial three steps in de novo pyrimidine
synthesis, is regulated by the phosphorylation reaction with different protein kinases, but the relationship with
mTOR protein kinase has not been known.
Results: CAD was recovered as a binding protein with mLST8, a component of the mTOR complexes, from HEK293
cells transfected with the FLAG-mLST8 vector. Association of these two proteins was confirmed by the co-
immuoprecipitaiton followed by immunoblot analysis of transfected myc-CAD and FLAG-mLST8 as well as that of the
endogenous proteins in the cells. Analysis using mutant constructs suggested that CAD has more than one region for
the binding with mLST8, and that mLST8 recognizes CAD and mTOR in distinct ways. The CAD enzymatic activity
decreased in the cells depleted of amino acids and serum, in which the mTOR activity is suppressed.
Conclusion: The results obtained indicate that mLST8 bridges between CAD and mTOR, and plays a role in the
signaling mechanism where CAD is regulated in the mTOR pathway through the association with mLST8.
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Target of rapamycin (TOR) is a serine/threonine protein
kinase genetically conserved among species from yeast
to mammal, which belongs to the phosphatidylinositol
3-kinase-related kinase family among the kinome, and con-
trols cell growth, proliferation, and survival. In mammal,
mechanistic TOR (mTOR) exists as two independently
regulated hetero-oligomeric complexes with common and
respective partners, called mTOR complex 1 (mTORC1)
and mTOR complex 2 (mTORC2), that are apparently sen-
sitive and insensitive to rapamycin, respectively [1].
mTORC1, that contains raptor, mLST8 also named as
GβL, and DEPTOR, directly phosphorylates the substrates
such as S6 kinase, 4E-BP1, and PRAS40, and links signals* Correspondence: ukikkawa@kobe-u.ac.jp
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distribution, and reproduction in any mediumincluding amino acids, growth factors, and energy to regu-
late various cellular functions such as protein synthesis,
transcription, metabolism, and autophagy. Rheb, a small
GTPase, activates mTORC1 as the GTP-bound form, and
tuberous sclerosis complex (TSC) gene products, TSC1
and TSC2, form a dimer to function as a GTPase activating
protein toward Rheb and thereby negatively regulate
mTORC1. mTORC2, on the other hand, has rictor,
mLST8, mSin1, DEPTOR, and Protor, and mediates
growth factor signals but not those of nutrients to catalyze
the phosphorylation of some AGC protein kinases such as
Akt, SGK, and PKCα [2,3].
mLST8 is a 36-kDa protein having seven WD40 repeats,
and is a common partner of mTORC1 and mTORC2
[4,5]. mLST8 appears to bind to the catalytic domain of
mTOR [6], and the overexpression and knockdown of
mLST8 suggested its positive function in mTORC1. The
following studies using mice lacking mLST8 showed thattral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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but not for the mTOR-raptor interaction, and that mLST8
has a role for mTORC2 rather than for mTORC1 [7]. The
precise role of mLST8, thus, still remains unclear espe-
cially in mTORC1.
In this study, we isolated the binding proteins to mLST8
by analyzing the proteins that co-immunoprecipitated
with FLAG epitope-tagged mLST8 from the transfected
HEK293 cells, and identified one of them as CAD, a
multifunctional protein with a deduced molecular mass of
243 kDa composed of the distinct regions in a single poly-
peptide: carbamoyl phosphate synthetase II (CPSase), as-
partate transcarbamoylase (ATCase), and dihydroorotase
(DHOase), which catalyze each of the initial three steps
in de novo pyrimidine synthesis [8,9]. CPSase is the first
and rate-limiting step for the nucleotide synthesis and
allosterically activated and inhibited by phosphoribosyl
5’-pyrophosphate and uridine nucleotides, respectively.
Moreover, CAD is regulated by the phosphorylation reac-
tion with different protein kinases such as MAP kinase
[10], PKA [11], and PKC [12]. Very recently, CAD has
been reported to be phosphorylated by S6 kinase in the
downstream of mTORC1 [13,14].
Here, we describe the association of CAD with mLST8,
which provides a physical environment where CAD is reg-
ulated by the protein phosphorylation reaction in the
mTOR signaling pathway, and an evidence that the CAD
enzymatic activity is controlled in the mTOR-signaling
pathway.Methods
cDNAs
The FLAG-tagged expression vectors of the wild type
mLST8 (FLAG-mLST8) and its mutants replacing Gly150
by Asp (G150D), Gly192 by Asp (G192D), and Phe320 by
Ser (F320S) constructed in pCMV5 were kindly provided
by Dr. Joseph Avruch (Massachusetts General Hospital,
USA). The mLST8 mutant replacing Ala182 by Asp
(A182D) was generated using a QuikChange site-directed
mutagenesis kit (Stratagene). The expression vector of
HA-tagged mTOR was constructed as described previ-
ously [15]. The cDNA encoding CAD was cloned by the
successive polymerase chain reactions using mouse brain
cDNAs (Quick-Clone, Clontech) as template. The primers
were designed to amplify CAD in three portions according
to the DNA sequence in the database (accession no.
NM_023525), and the products were assembled into
pcDNA3 with myc-epitope tag. The deletion mutants of
CAD, GLN/CPS (amino acids 1–1456), GLN/CPS’ (amino
acids 1–1461), DHO/ATC (amino acids 1457–2225),
DHO/ATC’ (amino acids 1462–2225), GLN (amino acids
1–373), CPS-A (amino acids 391–939), CPS-B (amino
acids 929–1461), DHO (amino acids 1457–1788), andATC (amino acids 1911–2225) were generated in the
pcDNA3-myc vector.Antibodies
The anti-FLAG (M2) and anti-myc (9E10) antibodies
were purchased from Sigma, and the anti-HA antibodies
(12CA5 and 3F10) were from Roche. The polyclonal
antibody against mLST8 was generated as described
[16]. The rabbit polyclonal anti-peptide antibody re-
cognizing CAD was produced by the antibody service of
Immuno-Biological Laboratories against the synthetic
peptide EVDSDPRAAYFRQAENG (amino acids 2194–
2210). Normal rabbit and mouse globulin were obtained
from Santa Cruz Biotechnology. The horseradish pero-
xidase (HRP)-conjugated anti-mouse and anti-rabbit
antibodies were obtained from Jackson ImmunoResearch
Laboratories and Bio-Rad, respectively.Cell culture and transfection
HEK293 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (Sigma) containing 10% fetal
bovine serum (FBS) (Gibco BRL) at 37°C in a 5% CO2
incubator. The cells were transfected with expression
vectors by lipofection using lipofectamine (Invitrogen)
according to the manufacturer’s protocol. For starvation
of the cells, they were first incubated in DMEM without
FBS for 16 h, and further incubated for 2 h with differ-
ent culture media [17].Immunoprecipitation
The following procedures were carried out at 0-4°C.
The cells were washed with ice-cold with Dulbecco’s
phosphate-buffered saline, and lysed with Buffer A
(20 mM Tris–HCl at pH 7.5, 120 mM NaCl, 1 mM
EDTA, 5 mM EGTA, 20 mM β-glycerophosphate, 0.3%
CHAPS, 1 mM phenylmethylsulfonyl fluoride, 2 μg/ml
aprotinin, 2 μg/ml leupeptin, and 1 mM dithiothreitol).
The supernatant was recovered by centrifugation at
15,000 × g for 25 min, and was incubated for 2 h with
Protein G-Sepharose (GE Healthcare) coupled with each
antibody, and the immunoprecipitate was washed three
times with Buffer A.Mass spectrometry
The immunoprecipitate was obtained by the anti-FLAG
antibody from the HEK293 cells transfected with FLAG-
mLST8. The resin was eluted with Buffer A containing
200 μg/ml FLAG peptide (Sigma), and the proteins were
separated by SDS-PAGE and visualized by silver staining.
Each protein band was recovered and mass spectromet-
ric analysis was carried out essentially as described [17].
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The cell extracts and immunoprecipitates were sepa-
rated by SDS-PAGE, and the proteins were transferred
to a polyvinylidene difluoride membrane and subjected
to immunoblotting using each primary antibody. After
incubation with the HRP-conjugated secondary anti-
bodies, detection of the proteins was carried out by the
chemiluminescence reaction.
mTOR kinase assay
The mTOR kinase assay was performed as previously de-
scribed [16,17]. Briefly, myc-CAD was immunoprecipitated
from the transfected HEK293 cells and eluted from the re-
sign with 300 μg/ml myc peptide (Fujiya, Japan). The im-
munoprecipitates obtained by the anti-HA antibody from
the HEK293 cells transfected with either HA-mTOR or
the empty vector were incubated with purified CAD in the
reaction mixture containing 10 mM HEPES at pH7.4,
50 mM β-glycerophosphate, 50 mM NaCl, 10 mM MnCl2,
100 μM ATP, and 370 kBq of [γ-32P]ATP. After the incuba-
tion for 30 min at 30°C, the samples were separated by
SDS-PAGE, transferred onto a polyvinylidene difluoride
membrane, and analyzed by autoradiography.
CPSase activity assay
The CPSase activity of the immunoprecipitated myc-CAD
was measured essentially as described [18,19]. Briefly,
HEK293 cells were transfected with the myc-CAD expres-
sion vector, cultured under the different conditions, and
lysed with Buffer A containing 20 mM NaF, 10 mM p-
nitrophenyl phosphoric acid, 30% dimethylsulfoxide, and
5% glycerol. The immunoprecipitate with the anti-myc
antibody was washed with 100 mM Tris–HCl at pH 8.0
containing 100 mM KCl, 7.5% dimethylsulfoxide, and 2.5%
glycerol, and then incubated for 20 min at 37°C with 500
μl of the reaction mixture containing 100 mM Tris–HCl at
pH 8.0, 100 mM KCl, 7.5% dimethylsulfoxide, 2.5% gly-
cerol, 1 mM dithiothreitol, 3.5 mM glutamine, 20.2 mM
aspartate, 1.5 mM ATP, 200 mM phosphoribosyl 5’-
pyrophosphate, 3.5 mM MgCl2, and 5 mM [
14C]NaHCO3
(118 MBq/mmol). The reaction was stopped by the
addition of 500 μl of 40% trichloroacetic acid, and the
tubes were heated at 95°C for 3 h. The incorporation of the
14C radioactivity into the acid stable materials was then
measured by liquid scintillation counting, and the relative
activity in each immunoprecipitate was normalized to the
amount of immunoprecipitated myc-CAD detected by
immunoblot.
Statistical analysis
The result is expressed as the mean ± SD of data obtained
from quadruplicate experiments. Statistical analysis was
performed using a paired Student t-test, and a P value less
than 0.01 was considered statistically significant.Results
Identification of CAD as an mLST8-binding protein
Proteins associating with mLST8 were searched by com-
paring the proteins retrieved in the anti-FLAG immuno-
precipitate prepared from HEK293 cells transfected with
the FLAG-mLST8 vector or an empty vector. The co-
immunoprecipitation with FLAG-mLST8 followed by
elution with the FLAG peptide recovered several proteins
as visualized by silver staining after SDS-PAGE (Figure 1A).
Mass spectrometric analysis revealed that the cellular
proteins included FLAG-mLST8 itself and mTOR, and
the proteins indicated as numbers 1 to 4 of approximate
molecular mass from 240 to 60 kDa in Figure 1A were
CAD, T-complex protein α and ε, T-complex protein η
and θ, and tubulin β5, respectively (data not shown). We
focused our attention on the protein number 1, CAD, be-
cause this protein is a rate-limiting enzyme for the pyrimi-
dine synthesis and is essential for the regulation of cell
growth [8,9]. Immunoblot analysis using the anti-CAD
antibody confirmed that CAD is co-immunoprecipitated
with FLAG-mLST8 by the anti-FLAG antibody recovered
from HEK293 cells transfected with the FLAG-mLST8
vector (Figure 1B). The anti-FLAG immunoprecipitate
also contained not only FLAG-mLST8 but the endogen-
ous mLST8, suggesting that CAD forms a multimeric
complex with mLST8. On the other hand, the anti-CAD
immunoprecipitate contained FLAG-mLST8 as expected,
but the endogenous mLST8 was not found. It seems that
the anti-mLST8 antibody is not sensitive enough to detect
mLST8 co-immunoprecipitated with the endogenously
expressed CAD. The association of CAD and mLST8 was
further examined by overexpressing both proteins with
different epitope tags in HEK293 cells: analysis showed
that FLAG-mLST8 and myc-CAD were detected in the
anti-myc and anti-FLAG immunoprecipitates, respectively
(Figure 1C). CAD endogenously expressed was also found
in the anti-mLST8 immunoprecipitate obtained from the
untransfected cells (Figure 1D).
The binding region of CAD with mLST8
CAD includes the distinct regions, CPSase, ATCase, and
DHOase, which catalyze each of the initial three steps in
de novo pyrimidine synthesis, and is composed of five
domains of GLN (glutamine amidotransferase), CPS-A,
CPS-B, DHO, and ATC [8]. A series of deletion mutants of
CAD were thus generated to examine the binding region
of mLST8 to CAD (Figure 2A, B). CAD was separated into
the amino- and calboxyl-terminal halves of GLN/CPS
(amino acids 1–1456) and DHO/ATC (amino acids 1457–
2225), and alternatively into GLN/CPS’ (amino acids 1–
1461) and DHO/ATC’ (amino acids 1462–2225) to avoid
damage of the domains by the artificial cleavage. The bind-
ing of mLST8 was, rather unexpectedly, found in the
immunoprecipitate of both amino- and calboxyl-terminal
Figure 1 Identification of CAD as an mLST8-binding protein. (A) Co-purification of CAD with FLAG-mLST8. The extract from HEK293 cells
transfected with or without FLAG-mLST8 vector was subjected to immunoprecipitation with the anti-FLAG antibody, and the proteins eluted
from resin with the FLAG peptide were visualized by silver staining after SDS-PAGE. FLAG-mLST8, mTOR, and the proteins recovered from the
immunoprecipitate (No.1 to 4) are shown. The positions of the size standards are indicated in kDa. (B) Association of CAD with overexpressed
mLST8. The extract from HEK293 cells transfected with the FLAG-mLST8 vector was subjected to immunoprecipitation with either the anti-CAD or
anti-FLAG antibody, and the immunoprecipitated proteins were analyzed by immunoblot with the anti-CAD and anti-mLT8 antibodies. NRG
(normal rabbit globulin) and NMG (normal mouse globulin) were employed as negative controls. *: a non-specific protein. (C) Association
between myc-CAD and FLAG-mLST8. The extract from HEK293 cells transfected with myc-CAD and FLAG-mLST8 vectors was subjected to
immunoprecipitation with either the anti-myc or anti-FLAG antibody, and the immunoprecipitated proteins were analyzed by immunoblot with
antibodies. (D) Association between the endogenous CAD and mLST8. The HEK293 cell extract without transfection and the immunoprecipitate
of the extract with the anti-mLST8 antibody were analyzed by immunoblot with the anti-CAD and anti-mLT8 antibodies. NRG was employed as a
negative control.
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domain such as GLN (amino acids 1–373), CPS-A (amino
acids 391–939), CPS-B (amino acids 929–1461), DHO
(amino acids 1457–1788), and ATC (amino acids 1911–
2225). Each domain, except for the ATC domain, showed a
significant binding activity. These results suggested that
mLST8 binds with CAD at more than one region rather
than a single recognition site in agreement with those in
Figure 1B.
The binding of mLST8 with CAD and mTOR
mLST8 is a component of the mTOR complexes, and
thus the binding between mLST8 and CAD (Figure 3A)
was compared with that between mLST8 and mTOR
(Figure 3B) using mLST8 point mutants. mLST8 has
some amino acid residues critical for the interaction
with mTOR such as Gly150, Gly192, and Phe320 [6] as
well as Ala182 (unpublished observation). The mutation
in these residues eliminated or heavily reduced the bin-
ding with mTOR (Figure 3B), but these mutants associ-
ated with CAD as the wild type protein (Figure 3A).
Namely, mLST8 associates with CAD in manner distinct
from that with mTOR.The measurement of the CPSase activity
The binding of CAD with mLST8 suggests that mTOR
controls not only protein synthesis but also that of the
pyrimidine nucleotides. It seemed possible that mTOR
phosphorylates CAD to regulate its enzymatic activity,
and thus in vitro incubation of myc-CAD with HA-
mTOR was carried out in the presence of [γ-32P]ATP
(Additional file 1). The phosphorylation of myc-CAD was,
however, not detected under the conditions that the
autophosphorylation of HA-mTOR [16] is clearly ob-
served. Then, the CPSase activity was measured as a
representative of this multienzymatic protein. HEK293
cells transfected with the myc-CAD vector were cultured
in the absence of serum, incubated further under the
different culture conditions, and then the immunoprecipi-
tates with the anti-myc antibody were prepared from the
cells and subjected to the assay of the CPSase activity
(Figure 4). The CAD protein recovered from the cells cul-
tured without amino acids, in which the mTORC1 activity
is suppressed [20], showed the CPSase activity significantly
lower than that obtained from the cells incubated with
amino acids. The stimulation of the cells with serum,
however, did not enhance the CPSase activity.
Figure 2 The interaction region of CAD with mLST8. (A) The schematic structure of CAD and the fragments employed. CAD and each
fragment are shown with the amino acid numbers. (B) Association of mLST8 with the CAD fragments. HEK293 cells were transfected with the
FLAG-mLST8 vector and Myc-tagged CAD expression vector of either the full length or each deletion mutant, and the cell extracts were
subjected to immunoprecipitation with the anti-myc antibody. The extracts and immunoprecipitates were analyzed by immunoblot with the anti-
myc or anti-FLAG antibody. The positions of CAD and its fragments are indicated by arrowheads. *: a non-specific protein.
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In this study, we identified CAD as a binding protein of
mLST8. CAD was also detected in the screening of the
binding proteins of FLAG-raptor, but the association was
weaker than that with FLAG-mLST8 (data not shown). It
is thus reasonable to assume that CAD associates with
mTORC1 including raptor through mLST8. As mLST8
and raptor, however, both contain WD-40 repeats known
to act as a site for protein-protein interaction [21], it is
difficult to exclude the possibility that these two proteins
recognize CAD, independently. Concerning the inter-
action between CAD and mLST8, the results obtained
suggest that CAD has more than one region for the recog-
nition of mLST8. It might be possible that the CAD
fragments interact with endogenously expressed CAD and
the CAD complexes thus generated associate with
mLST8, because CAD forms oligomers [8,9]. On the other
hand, mLST8 point mutants having little binding activity
with mTOR still associated with CAD. Therefore, mLST8
may bridge between mTOR and CAD, and CAD binds to
mLST8 in multiple ways.
We next examined the possibility that CAD is a substrate
for mTORC1, because CAD is known to be phosphory-
lated by some protein kinases [10-12]. The in vitro phos-
phorylation of CAD was, however, not detected after theincubation with the mTOR immunoprecipitated from the
transfected cells. Very recently, Robitaille et al. [13] have
carried out the quantitative phosphoproteomics of the
mTOR targets in the cells lacking raptor, and concluded
that mTOR1 indirectly phosphorylates and regulates CAD:
CAD is phosphorylated by S6 kinase at Ser1859 and
thereby pyrimidine synthesis is stimulated. Ben-Sahra et al.
[14], on the other hand, have identified Ser1859 and
Ser1900 as the phosphorylation sites in CAD. They indi-
cate that the modification of Ser1900 is stable but that of
Ser1859 is stimulated by insulin in a manner sensitive to
rapamycin, and propose that S6 kinase is responsible for
the phosphorylation of Ser1859. These two studies indicate
that CAD is controlled by the S6-kinase-mediated phos-
phorylation, but the practical interaction of CAD with
mTOR1 has not been analyzed. Taken the available
evidence together, it is reasonable to conclude that CAD
associated with mTORC1 through mLST8 is not phos-
phorylated directly by mTOR, but is recognized by S6
kinase that is activated by mTORC1. It is interesting to
examine the possibility that the binding proteins to mLST8
are phosphorylated by S6 kinase.
Ser1859 was identified as a phosphorylation site by S6
kinase [13,14], but this residue as well as Ser1406 have
been shown to be the PKA sites in CAD [11]. CAD is, in
Figure 3 Association of the mLST8 point mutants with CAD
and mTOR. (A) Association of the mLST8 point mutants with CAD.
HEK293 cells were transfected with the myc-CAD vector and the
FLAG-tagged expression vector of either the wild type or each point
mutant of mLST8 as indicated. The extracts and immunoprecipitates
with the anti-FLAG antibody were analyzed by immunoblot with the
anti-FLAG and anti-myc antibodies. (B) Association of the mLST8 point
mutants with mTOR. HEK293 cells were transfected with the HA-mTOR
vector and the FLAG-tagged expression vector of either the wild type
or each point mutant of mLST8 as indicated. The immunoprecipitates
with the anti-FLAG antibody were analyzed by immunoblot with the
anti-HA and anti-FLAG antibodies. *: a non-specific protein.
Figure 4 The CPSase activity in the amino acid-depleted cells.
HEK293 cells transfected with the myc-CAD vector were cultured in
the absence of serum for 16 h, and further incubated under
different conditions for 2 h. Cells were harvested as shown in the
bottom of the figure. 1: after serum starvation for 16 h, 2: after
further incubation with serum, 3: after further incubation without
serum, 4: after further incubation without serum and amino acids.
The immunoprecipitates with the anti-myc antibody from the cells
after each treatment were subjected to the CPSase assay. The
relative CPSase activity normalized to the amount of
immunoprecipitated myc-CAD are employing the activity of the
serum-starved cells as 100%. **, P < 0.01.
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and at Ser1873 by PKC [12]. It is appropriate that CAD
is phosphorylated in different signaling pathways by each
upstream protein kinase, because the deno nove pyrimi-
dine synthesis is the metabolic reactions critical for the
cells. Moreover, CAD is regulated in coordinated man-
ners through the phosphorylation by different protein
kinases: MAP kinase and PKA phosphorylate CAD in
a mutually antagonistic manner [22], and the PKC-
dependent phosphorylation enhances the MAP kinase-
mediated CAD activation [12]. It is thus important to
analyze the regulation mechanisms of CAD from a wide
point of view.
Concerning the de novo pyrimidine synthesis, Ben-Sahra
et al. [14] have showed the regulation of the de novo
pyrimidine synthesis through mTOR by comparing the
metabolites in TSC2-deficient and control cells labeled
with 15 N-glutamine. Robitaille et al. [13] have employed
HeLa cells metabolically labeled with the 15 N-glutamine
and reported the increase of dihydroorotate, orotate, and
UTP after depletion and stimulation with both serum and
amino acids. We revealed that the CPSase activity of
the immunoprecipitated CAD recovered from the amino
acid-depleted cells, in which the mTORC1 activity
is suppressed, is decreased by the in vitro assay using[14C] NaHCO3, indicating the contribution of the mTOR
complex in the regulation of the CAD activity. These re-
sults are compatible with those reported [13,14] and sup-
port the direct regulation of CAD by S6 kinase, but the
CPSase activity, in this study, was not enhanced by serum
stimulation. It is not clear why the CPSase activity was in-
sensitive to serum stimulation. Further studies are neces-
sary to clarify the regulation mechanisms of CAD through
the phosphorylation reaction by the protein kinases.
CAD has been shown to bind with other proteins such
as Rad9 [19] and androgen receptor [23]. Rad9 plays a role
in the DNA damage checkpoint response as a damage
sensor, and the binding of Rad9 to the CPSase domain
stimulates the CPSase activity, suggesting the relationship
between the DNA damage response and pyrimidine
synthesis. Androgen receptor shows a facilitated nuclear
localization and an enhanced transcriptional activity by
the interaction with CAD, but the role of this nuclear
receptor in nucleotide synthesis is not known. It is inter-
esting to know the relationship between mTORC1 and
these CAD binding proteins.
The evidences obtained indicate that mTORC1 is in-
volved in the regulation of the pyrimidine nucleotide
synthesis. The precise studies of mTORC1 and CAD will
bring key observation to clarify the interplay between
the synthesis of the proteins and nucleotides, which are
critical for the proliferation of the cells.
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The results obtained indicate that mLST8 bridges between
CAD and mTOR. CAD is not a direct phosphorylation
substrate of mTOR, but the association of CAD with
mLST8 provides a physical environment where CAD is
regulated through the phosphorylation reaction in the
mTORC1-signaling pathway.
Additional file
Additional file 1: Incubation of myc-CAD with HA-mTOR in the
kinase assay mixture. The kinase reaction using [γ-32P]ATP was carried
out in the presence of myc-CAD and HA-mTOR as indicated, and the
samples were analyzed by autoradiography and immunoblotting after
the separation by SDS-PAGE. The positions of myc-CAD and
phosphorylated HA-mTOR are indicated in the autoradiograph.
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